Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Net Margin (2016 - 2022)

Summit Therapeutics filings provide 7 years of Net Margin readings, the most recent being 7700.0% for Q3 2022.

  • Quarterly Net Margin fell 620275.0% to 7700.0% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 268266.82% through Jun 2023, down 26427914.0% year-over-year, with the annual reading at 11174.75% for FY2022, 627691.0% down from the prior year.
  • Net Margin hit 7700.0% in Q3 2022 for Summit Therapeutics, down from 5400.85% in the prior quarter.
  • Across five years, Net Margin topped out at 72.75% in Q3 2018 and bottomed at 42835.09% in Q2 2021.
  • Average Net Margin over 5 years is 6787.77%, with a median of 5535.1% recorded in 2019.
  • The largest annual shift saw Net Margin tumbled -3384744bps in 2021 before it soared 3743424bps in 2022.
  • Summit Therapeutics' Net Margin stood at 1223.93% in 2018, then plummeted by -363bps to 5669.35% in 2019, then fell by -29bps to 7319.46% in 2020, then plummeted by -48bps to 10796.41% in 2021, then rose by 29bps to 7700.0% in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Net Margin are 7700.0% (Q3 2022), 5400.85% (Q2 2022), and 8863.2% (Q1 2022).